Business Context and Reporting Period
This Form 8-K was filed by Vanda Pharmaceuticals Inc. on December 19, 2012. The report details actions taken by the Compensation Committee of the Board of Directors regarding executive compensation for the fiscal year ending December 31, 2012, and the fiscal year ending December 31, 2013.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
Executive Compensation Details
| Executive Officer | Position | 2012 Bonus Awarded | 2013 Base Salary | 2013 Target Bonus |
|---|---|---|---|---|
| Mihael Polymeropoulos, M.D. | President and CEO | $300,000 | $515,000 | 50% of Base Salary |
| James Kelly | SVP and CFO | $144,000 | $315,000 | 40% of Base Salary |
| Robert Repella | SVP and Chief Commercial Officer | $168,000 | $368,000 | 40% of Base Salary |
Material Changes
The filing reports the approval of 2012 annual bonuses and the establishment of 2013 base salaries and bonus targets. Prior to approval, the Compensation Committee reviewed an analysis of executive compensation compared to a peer group conducted by the consultant Towers Watson. No financial performance changes or operational shifts are detailed in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies. The only future-oriented data provided relates to the fixed 2013 compensation packages for named executive officers.
Investor Verification Checklist
- Verify the total cash outflow for 2012 bonuses ($612,000) against the company's cash position in the most recent 10-Q or 10-K.
- Confirm the 2013 salary increases and bonus structures align with the company's stated budget and cash flow projections.
- Review the Towers Watson peer group analysis referenced in the filing to understand the benchmarking methodology used for compensation decisions.
- Check subsequent filings for any changes to these compensation terms or the departure of the named officers.